RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      검색결과 좁혀 보기

      선택해제

      오늘 본 자료

      • 오늘 본 자료가 없습니다.
      더보기
      • 무료
      • 기관 내 무료
      • 유료
      • KCI등재

        스핑고신 키나아제 1 저해제인 PF-543과 PF-543 유사체 (22c)의 항암활성

        백동재(Dong Jae Baek),박은영(Eun Young Park) 대한약학회 2018 약학회지 Vol.62 No.5

        PF-543 selectively inhibits sphingosine kinase (SK)1 most potently among the known SK inhibitors. Although SK1 inhibitors have been reported to have anticancer effect, PF-543 has lower anticancer activity in some cancer cells compared with selective inhibition of SK1. Recent PF-543 derivatives were synthesized in Pfizer and observed inhibitory effects on SK1, suggesting that (S)-1-(4-((3-methyl-5-((phenylsulfonyl)methyl)phenoxy)methyl)benzyl)pyrrolidin-3-ol (22c) is more effective than PF-543. We investigated whether 22c improved the anticancer activity compared to PF-543 in proportion to the SK-1 inhibitory effect. The cytotoxic effect of PF-543, 22c and 5-fluorouracil was compared in HT29, HCT116 and AGS cells. PF-543 showed slightly higher cytotoxic effect than 22c in all cells. These results suggest that the SK inhibitory activity and the anticancer effect of the SK inhibitor are not necessarily proportional to each other. Therefore, development of SK inhibitor as an anticancer agent requires comparison of anticancer activity.

      • KCI등재

        디지털 치료기기의 특성 및 사용 평가

        정유림(Yu Rim Jeong),박은영(Eun-Young Park),백동재(Dong Jae Baek),방준석(Joon Seok Bang),김광준(Kwang Joon Kim) 대한약학회 2023 약학회지 Vol.67 No.5

        Digital therapeutics (DTx) are defined as high-quality software designed to prevent, manage, and treat medical disorders or diseases by providing evidence-based therapeutic interventions. In this study, an investigation was conducted to examine the characteristics of DTx, including their methods, safety-related data, and user evaluations of reSET®, reSET-O®, and Somryst®. These DTx solutions have recently obtained the first FDA approval and the first insurance code registration by government. However, there are limitations in terms of the quantitative scale of patient feedback evaluations and concerns about accuracy, as indicated by research findings. Nevertheless, with the active global development of DTx and the increasing scale of investment, pharmacists need to pay attention to and prepare for this innovative treatment concept.

      연관 검색어 추천

      이 검색어로 많이 본 자료

      활용도 높은 자료

      해외이동버튼